Initial experience with AI Pathway Companion: Evaluation of dashboard-enhanced clinical decision making in prostate cancer screening.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
01
2022
accepted:
24
06
2022
entrez:
20
7
2022
pubmed:
21
7
2022
medline:
23
7
2022
Statut:
epublish
Résumé
Rising complexity of patients and the consideration of heterogeneous information from various IT systems challenge the decision-making process of urological oncologists. Siemens AI Pathway Companion is a decision support tool that provides physicians with comprehensive patient information from various systems. In the present study, we examined the impact of providing organized patient information in comprehensive dashboards on information quality, effectiveness, and satisfaction of physicians in the clinical decision-making process. Ten urologists in our department performed the entire diagnostic workup to treatment decision for 10 patients in the prostate cancer screening setting. Expenditure of time, information quality, and user satisfaction during the decision-making process with AI Pathway Companion were recorded and compared to the current workflow. A significant reduction in the physician's expenditure of time for the decision-making process by -59.9% (p < 0,001) was found using the software. System usage showed a high positive effect on evaluated information quality parameters completeness (Cohen's d of 2.36), format (6.15), understandability (2.64), as well as user satisfaction (4.94). The software demonstrated that comprehensive organization of information improves physician's effectiveness and satisfaction in the clinical decision-making process. Further development is needed to map more complex patient pathways, such as the follow-up treatment of prostate cancer.
Identifiants
pubmed: 35857753
doi: 10.1371/journal.pone.0271183
pii: PONE-D-22-00078
pmc: PMC9299327
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271183Déclaration de conflit d'intérêts
NO authors have competing interests.
Références
Appl Clin Inform. 2022 Jan;13(1):91-99
pubmed: 35045583
Oncology. 2020;98(6):423-429
pubmed: 31734663
Appl Clin Inform. 2021 Jan;12(1):17-26
pubmed: 33440429
PLoS One. 2015 Jan 14;10(1):e0116656
pubmed: 25588043
BMC Health Serv Res. 2010 Aug 23;10:247
pubmed: 20731816
Methods Inf Med. 2001 May;40(2):90-8
pubmed: 11424310
Appl Clin Inform. 2020 Mar;11(2):200-209
pubmed: 32187632
JAMA. 2018 Dec 4;320(21):2199-2200
pubmed: 30398550
Appl Clin Inform. 2021 Mar;12(2):245-250
pubmed: 33763846
Appl Clin Inform. 2020 May;11(3):399-404
pubmed: 32492716
Implement Sci. 2018 Jun 25;13(1):86
pubmed: 29941007
BMJ. 2005 Apr 2;330(7494):765
pubmed: 15767266
BMJ. 2020 Sep 17;370:m3216
pubmed: 32943437
J Am Soc Nephrol. 2018 Feb;29(2):654-660
pubmed: 29097621